Free Trial

Exact Sciences (EXAS) Stock Price, News & Analysis

+1.52 (+3.39%)
(As of 07/12/2024 ET)
Today's Range
50-Day Range
52-Week Range
2.30 million shs
Average Volume
2.65 million shs
Market Capitalization
$8.55 billion
P/E Ratio
Dividend Yield
Price Target

Exact Sciences MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.93 Rating Score
87.2% Upside
$86.80 Price Target
Short Interest
7.70% of Shares Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
1.09mentions of Exact Sciences in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$90,105 Sold Last Quarter
Proj. Earnings Growth
From ($1.15) to ($0.27) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.46 out of 5 stars

Medical Sector

99th out of 917 stocks

Medical Laboratories Industry

4th out of 18 stocks

EXAS stock logo

About Exact Sciences Stock (NASDAQ:EXAS)

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

EXAS Stock Price History

EXAS Stock News Headlines

genetic testing test tube genome
Myriad Genetics Sees Stock Surge with Hereditary Cancer Tests (EXAS)
Myriad Genetics Inc. (NASDAQ: MYGN) is a leader in genetic testing and precision medicine. The company offers a wide variety of genetic tests including
Billionaire opens new pathway to wealth for investors
I’ve been a financial analyst for almost three decades, but I don’t think I’ve ever seen anything quite like this before.
Exact Sciences: Still No Reason To Own
Billionaire opens new pathway to wealth for investors
I’ve been a financial analyst for almost three decades, but I don’t think I’ve ever seen anything quite like this before.
Hedge Funds are Bullish on This Cancer Stock
See More Headlines
Receive EXAS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Exact Sciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Confirmed)
Fiscal Year End

Industry, Sector and Symbol

Medical laboratories
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
15 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$2.50 billion
Cash Flow
$0.02 per share
Book Value
$17.39 per share


Free Float
Market Cap
$8.55 billion

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for July 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

EXAS Stock Analysis - Frequently Asked Questions

How have EXAS shares performed this year?

Exact Sciences' stock was trading at $73.98 at the beginning of 2024. Since then, EXAS stock has decreased by 37.3% and is now trading at $46.36.
View the best growth stocks for 2024 here

How were Exact Sciences' earnings last quarter?

Exact Sciences Co. (NASDAQ:EXAS) announced its quarterly earnings results on Wednesday, May, 8th. The medical research company reported ($0.50) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.50). The medical research company earned $637.52 million during the quarter, compared to analyst estimates of $624.95 million. Exact Sciences had a negative net margin of 9.48% and a negative trailing twelve-month return on equity of 7.12%.

What is Kevin T. Conroy's approval rating as Exact Sciences' CEO?

328 employees have rated Exact Sciences Chief Executive Officer Kevin T. Conroy on Kevin T. Conroy has an approval rating of 97% among the company's employees. This puts Kevin T. Conroy in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 69.0% of employees surveyed would recommend working at Exact Sciences to a friend.

Does Exact Sciences have any subsidiaries?

Exact Sciences subsidiaries include Ashion Analytics, Thrive Earlier Detection Corporation, Base Genomics Limited, Paradigm Diagnostics Inc., Viomics Inc., Biomatrica Inc., Armune BioScience, and more.

Who are Exact Sciences' major shareholders?

Top institutional investors of Exact Sciences include DNB Asset Management AS (0.13%), Thompson Investment Management Inc. (0.11%), Beech Hill Advisors Inc. (0.03%) and QRG Capital Management Inc. (0.02%). Insiders that own company stock include Kevin T Conroy, Sarah Condella, Katherine S Zanotti, James Edward Doyle, Everett Cunningham, D Scott Coward, Daniel J Levangie, Jacob A Orville, Brian Baranick, Jeffrey Thomas Elliott and James Herriott.
View institutional ownership trends

How do I buy shares of Exact Sciences?

Shares of EXAS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Exact Sciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Exact Sciences investors own include Novavax (NVAX), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Salesforce (CRM), PayPal (PYPL) and Block (SQ).

This page (NASDAQ:EXAS) was last updated on 7/13/2024 by Staff

From Our Partners